Dermalogica's FutureCode Booster Damage-Correcting Longevity Serum costs $89 (£89) for 30ml, launched May 15 across the brand's spas, skin centers and Ulta, and a Stylist writer just credited it with making her skin "smoother than any exfoliator" she's tried. That comparison is worth pausing on, because Dermalogica doesn't market the serum as an exfoliant at all. It sells FutureCode Booster as a barrier-repair and cellular-support treatment, paired at launch with a separate product, the Phyto Nature E² Exosome Exfoliant, specifically for resurfacing. The smoothing effect one tester felt is a real, personal result. It isn't the job the formula was built to do, according to the company's own two-step system.
The serum's selling point is its "Longevity Renew Complex," a blend of teprenone, niacinamide and sunflower sprout extract that Dermalogica says supports NAD+ levels in skin cells. Teprenone has a long history, just not in skincare: it's the active ingredient in Selbex, a prescription ulcer medication used in Japan since 1984. A fact sheet from the ingredient supplier MakingCosmetics claims it can extend cell lifespan by a third, but that figure comes from the company selling the raw ingredient, not from a published clinical trial, and no literature reviewed connects teprenone to NAD+ biology specifically. The ingredient dictionary at Paula's Choice lists it without endorsing any longevity claim.
Topical NAD+ is itself an unsettled category this year. A 2026 review in the journal Cosmoderma describes online NAD+ skincare claims as overhyped, noting that NAD+ is a 663-dalton, water-soluble molecule that is "unstable" and poorly suited to penetrating skin, with clinical evidence still limited. Dermatologists interviewed by NBC News and Marie Claire UK made a similar point: topical NAD+ precursors tend to perform like niacinamide, an inexpensive, decades-old ingredient already proven to support the skin barrier and even out tone. Niagen Bioscience, the company behind the NAD+ supplement Tru Niagen, only released its own topical NAD+ product as a limited test run in March, explicitly to gather consumer feedback rather than to claim it works. If a company built around NAD+ research is still gathering data, a $89 serum borrowing the same science is worth a second look before anyone credits it with reversing seven days of damage.
That seven-day figure matters because Dermalogica's own marketing doesn't agree with itself on it. UK retail copy for the serum claims it is "clinically proven to transform the look of skin in 7 days." Elsewhere, including the brand's own FAQ and a retailer's staff trial published by Escentual, the promise softens into something closer to a reward for weeks of consistent use. A reader deciding whether to spend $89 on a 30ml bottle deserves to know which claim the company is actually standing behind, and right now the answer depends on which page you land on.
There's also a practical formula note that reviews tend to skip: the serum contains citrus peel oils that sit on the EU's fragrance allergen list. For a product pitched at skin repair and barrier support, that's a detail worth flagging to anyone with reactive or sensitized skin, since a serum meant to calm and restore shouldn't also be a likely source of irritation.
Context helps explain why this product exists now. "Skin longevity" and "biohacking" are the beauty industry's defining language shift for 2026, replacing "anti-aging" with talk of cellular senescence and mitochondrial health, according to a trend report from in-cosmetics connect. Ingredient suppliers are building entire platforms around that framing for the year ahead, which makes FutureCode Booster one entry in a wave of similarly positioned launches rather than a singular breakthrough. Dermalogica itself sits inside Unilever's Prestige Beauty division, acquired in 2015, alongside brands including Paula's Choice, Tatcha and K18. Unilever has spent the past year trimming that portfolio, selling Kate Somerville in October 2025 and reportedly shopping around Ren Skincare, according to trade coverage from Cosmetics Business, even as it introduces premium, trend-driven SKUs like this one at prestige pricing.
None of that means the serum does nothing. Niacinamide alone has solid research behind it for barrier function and tone, and a well-formulated serum built around it could plausibly leave skin feeling smoother, which may be exactly what the Stylist reviewer experienced. The gap is between that modest, plausible result and the loftier claims riding alongside it: a longevity complex named for a mechanism (NAD+ support) that independent dermatologists describe as unproven at the topical level, a headline ingredient (teprenone) with no published link to that mechanism at all, and a seven-day transformation promise that the brand itself can't keep consistent across its own pages. At $89 for 30ml, sold through spas and a single major retailer, the serum is priced like a breakthrough. The ingredient list and the brand's shifting claims suggest it should be judged, for now, like a well-dosed niacinamide treatment wearing a longevity label.
